Skip to main content
Top
Published in: Familial Cancer 2/2015

01-06-2015 | Original Article

Germline RAD51B truncating mutation in a family with cutaneous melanoma

Authors: Karin A. W. Wadt, Lauren G. Aoude, Lisa Golmard, Thomas V. O. Hansen, Xavier Sastre-Garau, Nicholas K. Hayward, Anne-Marie Gerdes

Published in: Familial Cancer | Issue 2/2015

Login to get access

Abstract

Known melanoma predisposition genes only account for around 40 % of high-density melanoma families. Other rare mutations are likely to play a role in melanoma predisposition. RAD51B plays an important role in DNA repair through homologous recombination, and inactivation of RAD51B has been implicated in tumorigenesis. Thus RAD51B is a good candidate melanoma susceptibility gene, and previously, a germline splicing mutation in RAD51B has been identified in a family with early-onset breast cancer. In order to find genetic variants associated with melanoma predisposition, whole-exome sequencing was carried out on blood samples from a three-case cutaneous melanoma family. We identified a novel germline RAD51B nonsense mutation, and we demonstrate reduced expression of RAD51B in melanoma cells indicating inactivation of RAD51B. This is only the second report of a germline truncating RAD51B mutation. While this case report is consistent with melanoma being part of the RAD51B cancer spectrum further population-based screening of large case–control sample series will be needed to definitively establish if this is the case.
Literature
2.
5.
go back to reference Aoude L, Pritchard A, Robles-Espinoza C, et al. Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. JNCI. (Accepted Aug 2014) Aoude L, Pritchard A, Robles-Espinoza C, et al. Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. JNCI. (Accepted Aug 2014)
8.
go back to reference Schoenmakers EF, Huysmans C, Van de Ven WJ (1999) Allelic knockout of novel splice variants of human recombination repair gene RAD51B in t(12; 14) uterine leiomyomas. Cancer Res 59:19–23PubMed Schoenmakers EF, Huysmans C, Van de Ven WJ (1999) Allelic knockout of novel splice variants of human recombination repair gene RAD51B in t(12; 14) uterine leiomyomas. Cancer Res 59:19–23PubMed
11.
go back to reference Figueroa JD, Garcia-Closas M, Humphreys M et al (2011) Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Hum Mol Genet 20:4693–4706. doi:10.1093/hmg/ddr368 CrossRefPubMedCentralPubMed Figueroa JD, Garcia-Closas M, Humphreys M et al (2011) Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Hum Mol Genet 20:4693–4706. doi:10.​1093/​hmg/​ddr368 CrossRefPubMedCentralPubMed
21.
go back to reference Consortium BC linkage (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310–1316CrossRef Consortium BC linkage (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310–1316CrossRef
Metadata
Title
Germline RAD51B truncating mutation in a family with cutaneous melanoma
Authors
Karin A. W. Wadt
Lauren G. Aoude
Lisa Golmard
Thomas V. O. Hansen
Xavier Sastre-Garau
Nicholas K. Hayward
Anne-Marie Gerdes
Publication date
01-06-2015
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 2/2015
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-015-9781-4

Other articles of this Issue 2/2015

Familial Cancer 2/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine